Cargando…

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma

Loss-of-function mutations in the RB1 tumour suppressor are key drivers in cancer, including osteosarcoma. RB1 loss-of-function compromises genome-maintenance and hence could yield vulnerability to therapeutics targeting such processes. Here we demonstrate selective hypersensitivity to clinically-ap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zoumpoulidou, Georgia, Alvarez-Mendoza, Carlos, Mancusi, Caterina, Ahmed, Ritika-Mahmuda, Denman, Milly, Steele, Christopher D., Tarabichi, Maxime, Roy, Errin, Davies, Lauren R., Manji, Jiten, Cristalli, Camilla, Scotlandi, Katia, Pillay, Nischalan, Strauss, Sandra J., Mittnacht, Sibylle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642453/ https://www.ncbi.nlm.nih.gov/pubmed/34862364 http://dx.doi.org/10.1038/s41467-021-27291-8

Ejemplares similares

Selective Elimination of Osteosarcoma Cell Lines with Short Telomeres by Ataxia Telangiectasia and Rad3-Related Inhibitors
por: Goncalves, Tomas, et al.
Publicado: (2020)

RB in DNA repair
por: Huang, Paul H., et al.
Publicado: (2015)

Direct interaction between the catalytic subunit of Protein Phosphatase 1 and pRb
por: Vietri, Michele, et al.
Publicado: (2006)

A 3D Collagen-Based Bioprinted Model to Study Osteosarcoma Invasiveness and Drug Response
por: Pellegrini, Evelin, et al.
Publicado: (2022)

Leveraging single‐cell sequencing to unravel intratumour heterogeneity and tumour evolution in human cancers
por: Bowes, Amy L, et al.
Publicado: (2022)

Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma
por: Landuzzi, Lorena, et al.
Publicado: (2021)

An overview of mutational and copy number signatures in human cancer
por: Steele, Christopher D, et al.
Publicado: (2022)

Direct Involvement of Retinoblastoma Family Proteins in DNA Repair by Non-homologous End-Joining
por: Cook, Rebecca, et al.
Publicado: (2015)

ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity
por: Zucchini, Cinzia, et al.
Publicado: (2019)

Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines
por: Garofalo, Cecilia, et al.
Publicado: (2015)

MiRNAs in Canine and Human Osteosarcoma: A Highlight Review on Comparative Biomolecular Aspects
por: Leonardi, Leonardo, et al.
Publicado: (2021)

RB loss sensitizes cells to replication-associated DNA damage after PARP inhibition by trapping
por: Zamalloa, Luis Gregory, et al.
Publicado: (2023)

Workflow for High-content, Individual Cell Quantification of Fluorescent Markers from Universal Microscope Data, Supported by Open Source Software
por: Stockwell, Simon R., et al.
Publicado: (2014)

Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
por: Hattinger, Claudia Maria, et al.
Publicado: (2023)

Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy
por: Fernanda Amary, M, et al.
Publicado: (2014)

To Rb or not to Rb
por: Wells, William A.
Publicado: (2002)

Complete Genome Sequences of T4-Like Bacteriophages RB3, RB5, RB6, RB7, RB9, RB10, RB27, RB33, RB55, RB59, and RB68
por: Yaung, Stephanie J., et al.
Publicado: (2015)

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer
por: Miao, Chenkui, et al.
Publicado: (2022)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
por: Park, Hye Jeong, et al.
Publicado: (2018)

miR-142 suppresses proliferation and induces apoptosis of osteosarcoma cells by upregulating Rb
por: Gao, Yan-Fang, et al.
Publicado: (2018)

Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing
por: Hattinger, Claudia Maria, et al.
Publicado: (2022)

Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells
por: Evangelisti, Camilla, et al.
Publicado: (2020)

PLP2-derived peptide Rb4 triggers PARP-1-mediated necrotic death in murine melanoma cells
por: Maia, Vera S. C., et al.
Publicado: (2022)

Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer
por: Asghar, Uzma S., et al.
Publicado: (2022)

RB1-mediated cell-autonomous and host-dependent oncosuppressor mechanisms in radiation-induced osteosarcoma
por: Kansara, Maya, et al.
Publicado: (2014)

A Rb1 promoter variant with reduced activity contributes to osteosarcoma susceptibility in irradiated mice
por: Rosemann, Michael, et al.
Publicado: (2014)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
por: Engert, Florian, et al.
Publicado: (2016)

Osteosarcoma without prior retinoblastoma related to RB1 low‐penetrance germline pathogenic variants: A novel type of RB1‐related hereditary predisposition syndrome?
por: Imbert‐Bouteille, Marion, et al.
Publicado: (2019)

Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma
por: Hattinger, Claudia M., et al.
Publicado: (2016)

Deletion of Rb1 gene in late osteosarcoma from survivor of unilateral retinoblastoma--a case report.
por: Lee, S. Y., et al.
Publicado: (1996)

Integrated approaches to miRNAs target definition: time-series analysis in an osteosarcoma differentiative model
por: Grilli, A., et al.
Publicado: (2015)

The levels of MDM2 protein are decreased by a proteasome-mediated proteolysis prior to caspase-3-dependent pRb and PARP cleavages.
por: Cho, J. W., et al.
Publicado: (2001)

Mechanism-Based Screen for G1/S Checkpoint Activators Identifies a Selective Activator of EIF2AK3/PERK Signalling
por: Stockwell, Simon R., et al.
Publicado: (2012)

The beta-decay of $^{95}$Rb and $^{97}$Rb
por: Kratz, K L, et al.
Publicado: (1983)

Chromatin remodeling protein HELLS is upregulated by inactivation of the RB-E2F pathway and is nonessential for osteosarcoma tumorigenesis
por: Wu, Stephanie C., et al.
Publicado: (2018)

Generation of Osteosarcomas from a Combination of Rb Silencing and c‐Myc Overexpression in Human Mesenchymal Stem Cells
por: Wang, Jir‐You, et al.
Publicado: (2016)

Novel RB1 and MET Gene Mutations in a Case with Bilateral Retinoblastoma Followed by Multiple Metastatic Osteosarcoma
por: Mokánszki, Attila, et al.
Publicado: (2020)

IGF2BP3 From Physiology to Cancer: Novel Discoveries, Unsolved Issues, and Future Perspectives
por: Mancarella, Caterina, et al.
Publicado: (2020)

CCN proteins in the musculoskeletal system: current understanding and challenges in physiology and pathology
por: Giusti, Veronica, et al.
Publicado: (2021)

miR-486-5p expression is regulated by DNA methylation in osteosarcoma
por: Namløs, Heidi M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tou7d4gfdjepr9kfd85t2acnar